An open-label phase II trial of motexafin gadolinium (MGd) in patients with relapsed or refractory multiple myeloma

Trial Profile

An open-label phase II trial of motexafin gadolinium (MGd) in patients with relapsed or refractory multiple myeloma

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Motexafin gadolinium (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 02 Nov 2016 Last checked against ClinicalTrials.gov record.
    • 07 Jun 2007 Status changed from recruiting to completed.
    • 26 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top